DNA mismatch repair (MMR) stabilizes the cellular genome. Mice defective in the MMR gene PMS2 are susceptible to spontaneous thymic lymphoma and sarcomas. To determine the sensitivity of PMS2 knockout mice to environmental carcinogens and the protective eect of O 6 -methylguanine DNA methyltransferase (MGMT), heterozygous PMS2 knockout mice and human MGMT (hMGMT) transgenic mice were mated and the PMS2 7/7 and PMS2 +/+ with or without hMGMT ospring were treated at 5 weeks of age with 50 mg/kg N-methyl-N-nitrosourea (MNU). MNU produces carcinogenic O 6 -methylguanine (O 6 -meG) adducts, resulting in thymic lymphoma in mice, which can be prevented in normal mice by overexpression of hMGMT. A signi®cantly higher incidence of thymic lymphomas was observed in MNU-treated PMS2 7/7 mice, compared to wildtype PMS2 +/+ mice (100 vs 52%; P50.001). The mean latency of lymphomas was also signi®cantly shortened in PMS2 7/7 mice (81 vs 102 days, P50.01). Transgenic expression of hMGMT signi®cantly but incompletely blocked MNU lymphomagenesis in PMS2 7/7 mice. The incidence of lymphomas in PMS2 7/7 /hMGMT + mice was reduced to 80% (P50.01) and mean latency increased to 91 days (P50.05). Thymic lymphomagenesis was eciently blocked in PMS2 +/+ /hMGMT + mice with rapid repair of O 6 -meG. Since O 6 -meG:T mismatches in MMR + cells may trigger mismatch repair resulting in abortive repair and cell death whereas in the absence of MMR, these mismatches are converted to A:T, we predicted that G to A point mutations in codon 12 of the K-ras gene would occur. In this study, we found G to A point mutations in codon 12 of the K-ras gene in many tumors. Thus, in MMR de®cient tissues, methylating agents induce point mutations in cells with a higher rate of cell survival which together are potently carcinogenic in the thymus. These data suggest that PMS2 defective lymphomas may arise by the concerted action of environmental and perhaps endogenous methylation of DNA coupled to genomic instability.
Keywords: PMS2 de®ciency; hMGMT; MNU; lymphoma DNA mismatch repair (MMR) and O 6 -alkylguanine DNA alkyltransferase (AGT) repair play an important role in the prevention of tumorigenesis (Modrich and Lahue, 1996; Pegg et al., 1995) . Defects in mismatch repair are causative of hereditary non-polyposis colorectal cancer (HNPCC). Mice defective in mismatch repair gene, PMS2 or MSH2, are susceptible to spontaneous thymic lymphoma, skin tumor and intestinal tumors (Baker et al., 1995; de Wind et al., 1995; Prolla et al., 1998; Reitmair et al., 1995 Reitmair et al., , 1996 .
AGT, the product of the O 6 -methylguanine DNA methyltransferase gene (MGMT), speci®cally repairs O 6 -methylguanine (O 6 -mG) (Pegg, 1990) by transferring directly the methyl group from the O 6 -mG moieties of double-stranded DNA to its cysteine residue at 145 (Lindahl, 1982) . O 6 -mG is regarded as one of the most critical lesions produced by endogenous and environmental methylating agents (Eadie et al., 1984; Ellison et al., 1989; Qin et al., 1990 Qin et al., , 1994 . Unless repaired, O 6 -mG preferentially pairs with thymine (T) instead of cytosine (C) during DNA replication, resulting in a G:C to A:T transition mutation. Some of these mutations may result in activation of proto-oncogenes and cause malignant transformation, since G:C to A:T transition mutations have typically been detected at the second guanine of codon 12 (GGT) of the K-ras or Hras oncogenes in rodent tumors induced by N-nitroso carcinogens (Belinsky et al., 1989; Sakumar et al., 1983; Wang et al., 1990) . Carcinogenic N-alkyl-N-nitrosoureas are known to induce tumors preferentially in tissues with low AGT activity (Gerson et al., 1986; Thomale et al., 1990) , indicating that repair of O 6 -alkylguanine protects cell from malignant conversion. Moreover, it has been documented that AGT activity is decreased in non-cancerous tissues derived from patients with cancer (Rudiger et al., 1989) . We and others have shown that MGMT-transgenic mice expressing high levels of MGMT are resistant to alkylating carcinogens (Dumenoc et al., 1991 (Dumenoc et al., , 1993 Lim et al., 1990; Matsukuma et al., 1989; Nakatsuru et al., 1991 Nakatsuru et al., , 1993 , suggesting that MGMT activity correlates with susceptibility of animals to N-nitroso compound induced tumors. Furthermore, targeted disruption of MGMT gene renders mice hypersensitive to the toxicity and carcinogenic eects of aklylating agents, further con®rming that AGT activity is a very important inhibitor of tumor induction (Iwakuma et al., 1997; Sakumi et al., 1997; Tsuzuki et al., 1996) .
In the present study, making use of mice defective in PMS2, a DNA mismatch repair gene, and human MGMT (hMGMT) cDNA transgenic mice, we investigated the eects of PMS2 gene de®ciency on the sensitivity to N-methyl-N-nitrosourea (MNU) carcinogenicity and determined the protective eects of high expression of hMGMT on this sensitivity. The construct of hMGMT-CD2 transgenic mice has been described earlier (Dumenoc et al., 1993) . Ospring of founder C57BL/66SJL F1 mice were screened for the transgene by Southern analysis and PCR ampli®cation of hMGMT cDNA. The PMS2 knockout mice were generated in 129 ES cells, chimeric mice propagated in C57BL/6 and ospring crossed to generate the line (Baker et al., 1995) ]. The genetic variation should be spread equally across all groups since they were littermates. The genotypes of all the mice were determined by PCR ampli®cation of the tail DNA as described by Baker et al. (1995) . All experimental mice were given a single ip injection of MNU at a dose of 50 mg/kg body weight at 5 weeks of age. The mice were daily observed for respiratory distress, the clinical syndrome associated with thymic lymphoma. Such animals were euthanized under carbon dioxide (CO 2 ) anesthesia and autopsied, and an immediate necropsy was done. At autopsy, thymic lymphomas were massive, encasing the heart and the lungs. Extensive invasion into many other organs including liver, lung, kidney, lymph nodes and brain were found in some of the mice. Parts of the tumors and various organs were frozen in liquid nitrogen and stored at 7708C for analysis of K-ras mutations and AGT activity. These tissues were also ®xed in 10% buered formalin and were routinely processed for light microscopy examination. The sections were cut at 3 mm and stained with H&E. The tumor cells were intermediate and large noncleaved cells with spontaneous apoptosis, consistent with a lymphoblastic lymphoma. Disaggregated tumor cells were analysed by¯uorescence-activated cell sorter (FACS) for surface marker expression using goat antimouse Thy-1 or B220 antibodies conjugated with phycoerythrin (PE) or Fluorescein (FITC) (PharMingen, San Diego, CA, USA), and the Becton Dickinson FACSorter. This analysis demonstrated that thymic lymphomas were Thy-1 positive and B-cell surface marker (B220) negative, suggesting their T-cell origin (data not shown). These tumors may represent the murine counterpart of human preT-cell lymphoblastic lymphoma (LBL), as also reported for the spontaneous +/+ /hMGMT + mouse developed thymic lymphoma at day 143 posttreatment with an incidence of 2.5% (the thymic lymphoma-free survival rate was 97.5%), compared with the 52% incidence of lymphomas in PMS2 +/+ mice (the thymic lymphoma-free survival rate was 48%) (P50.0001). (c) Thymic lymphoma induction by MNU in PMS2 /hMGMT + and PMS2 7/7 mice showed similar incidence of 25% by 1 year, as shown in Figure 1 by 75% thymic lymphoma-free survival rate. These data are similar to the spontaneous incidence of lymphomas previously reported (Baker et al., 1995) . Thus, there was no protective eect of high hMGMT expression on spontaneous thymic lymphoma development in PMS2 7/7 mice. Figure 2 shows the dierence in sensitivity to MNU induced lymphomas between 42 PMS2 7/7 and 26 PMS2 +/+ mice treated with 50 mg/kg MNU. All of the PMS2 7/7 mice (100%) died from thymic lymphomas by 181 days post treatment, whereas the incidence of lymphomas in PMS2 +/+ mice given MNU was signi®cantly lower at 1 year, 52% P50.05. There was also a signi®cant dierence mean latency (81 vs 102 days, P50.01) of tumors in PMS2 7/7 vs PMS2 +/+ mice. To determine whether the incidence of lymphomas following MNU in PMS2 7/7 mice was simple additive or represented synergistic hypersensitivity, we evaluated the incidences separately. The additive tumor incidence (Pa) from the spontaneous incidence of thymic lymphomas in PMS2 7/7 mice (Ps) and the MNU-induced incidence in PMS2 +/+ mice (Pm), was calculated according to the multiplication rule and the addition rules (Strike, 1991) : Pa=(Ps+Pm)7 (Ps6Pm). The calculated data were plotted as calculated Kaplan-Meier cumulative survival curves (Figure 2 ). There was a highly signi®cant dierence between the calculated additive curve and the MNU tumorigenesis curve in PMS2 7/7 mice (P50.0001). In addition, cumulative hazard analysis was also used to determine whether the incidence of lymphomas in MNU treated PMS2 7/7 mice was more than additive of the spontaneous incidence of thymic lymphomas in PMS2 7/7 mice and the MNU-induced incidence in PMS2 +/+ mice. This is shown in Figure 3 . The hazard levels o for the additive risk curve but continues to increase for the observed incidence curve for MNU treated PMS2 7/7 mice. The dierence was highly signi®cant (P50.0001). These data suggest that PMS2 7/7 mice are in fact hypersensitive to MNUinduced thymic lymphomas resulting in a synergistic increase in incidence and reduction in latency.
High expression of hMGMT transgene can efficiently protect normal mice from lymphoma induction by the same treatment (Dumenco et al., 1993) . In the present study, out of 40 PMS2 +/+ /hMGMT + mice only one mouse developed thymic lymphoma with a thymic lymphoma-free survival rate of 97.5%, compared with 7/7 mice and MNUinduced thymic lymphoma development in PMS2 +/+ mice (open square) were replotted. The MNU-treated 42 PMS2 7/7 mice showed signi®cantly higher incidence (100%) of thymic lymphomas than the equally treated 26 PMS2 +/+ mice (52%) (P50.05). The mean latency of lymphoma was shorter in PMS2 7/7 mice than in normal mice (82 vs 102 days, P50.01). In order to evaluate the additive eect of the spontaneous incidence in PMS2 7/7 mice and MNU-induced incidence in PMS2 +/+ mice, an additive incidence was calculated according to the multiplication rule and addition rule of statistics. Pa=(Ps+Pm)7(Ps6Pm). Pa: Possible additive incidence; Ps: Spontaneous incidence; Pm: MNU-induced incidence. The calculated additive incidence indicates that the incidence of thymic lymphomas should be 66%. There was a signi®cant dierence between the calculated additive survival curve and the actual survival curve of MNU-treated PMS2 7/7 mice (P50.0001), indicating synergism in tumor incidence in the combination over that of MNU or PMS2 7/7 alone. To further assess the increased risk of developing lymphoma, the hazard curve for each cohort was plotted (Figure 3) . The hazard curves also indicate the marked degree of synergism of the MNU eect in the PMS2 7/7 background PMS2 deficiency and MNU lymphoma induction X Qin et al the 48% rate in the non-transgenic mice. The dierence was highly signi®cant (P50.0001) (Figure 1 ). Expression of hMGMT in the PMS2-de®cient mice was con®rmed by AGT activity assay as described earlier (Gerson et al., 1986) . Thymuses of 8 PMS2 /hMGMT + mice was 80% (thymic lymphoma-free survival was 20%) compared to a 100% incidence (0 survival) in the PMS2 7/7 mice (P50.001). There was a signi®cant decrease in mean latency of lymphomas in MNU-treated PMS2 7/7 mice compared to MNU-treated PMS2 7/7 /hMGMT + mice (81 vs 91 days, P50.05) (Figure 1) . However, the protection observed in hMGMT + mice was obviously incomplete in PMS2 7/7 mice compared to PMS2 +/+ mice. For K-ras mutation analysis, activating G to A point mutations in codon 12 of K-ras, the most common site of activated ras mutations in this model system (Belinsky et al., 1989; Sakumar et al., 1983; Wang et al., 1990) , were investigated using PCR-RFLP as previously described (Zaidi et al., 1995) . A modi®cation was introduced by changing a primer for the second PCR ampli®cation, which makes the G to A point mutation at the second position in codon 12 of K-ras recognized by the restriction enzyme, Fok-I, as shown in Figure 4 . Fisher's exact test and Student ttest were used statistic assay. Thirty-nine lymphoma samples from PMS2 7/7 mice, 31 samples from PMS2 7/7 /hMGMT + mice and 25 samples from PMS2 +/+ mice were analysed. As shown in Table 1 , a much higher mutation frequency of K-ras codon 12 was found in lymphomas of PMS2 7/7 mice compared to PMS2 +/+ mice (26/70 vs 3/25). Of interest, the codon 12 K-ras mutation frequency was higher in the PMS2 7/7 /hMGMT + group, 51.6% (16 out of 31), compared to the PMS2 7/7 group, 25.6% (10 out of 39), (P50.05). As expected, all the K-ras mutations detected in the present study were G to A transition point mutations (GGT to GAT), consistent with the speci®city of DNA alkylation by MNU. There was no correlation between K-ras mutations and tumor latency in either PMS2 7/7 or PMS2 +/+ mice. As shown in Figure 4c -PCR#1, heterozygosity of K-ras codon 12 was not clearly apparent for the samples in lanes b and d, indicating that homozygous mutations or loss of the normal allele occurred in PMS2 7/7 mice. Mismatch repair stabilizes the cellular genome by correcting single mismatches and single and dinucleotide slippage during replication. PMS2 7/7 mice showed destabilized microsatellite DNA sequences and a 100-fold elevation in mutation frequency in all tissues examined compared with both wild-type and heterozygous litter mates even in the absence of mutagen treatment (Baker et al., 1995 (Baker et al., , 1996 Narayanan et al., 1997; Prolla et al., 1998 -meG in the parental strand is preferentially paired with thymine (T) instead of cytosine (C) by any of the polymerases, producing O 6 -meG:T mispairs (Eadie et al., 1984; Ellison et al., 1989) . During the subsequent round of repair or replication synthesis, this results in a G to A transition mutation. In MMR-pro®cient cells, newly formed O 6 -meG:T mispairs are recognized after DNA replication, resulting in single-strand patch formation in the newly -meG. This futile cycle is associated with DNA double strand breaks whenever the single strand extends to the replication site, either leading to S phase arrest and, ultimately, induction of apoptosis (Meikrantz et al., 1998) and cell death. Surviving cells are loaden with G to A mutations or can undergo nonhomologous recombination and chromosomal rearrangements at the site of the patches (Galloway et al., 1995) , contributing to the carcinogenesis of methylating agents in MMR competent animals. In contrast, MMR de®cient cells, due to the lack of initiation of MMR, are tolerance to methylating agents (Fink et al., 1998; Liu et al., 1996) and a large number of O 6 -meG DNA adducts, which we have previously reported to be 96 pg/mg guanine bases 3 h after MNU treatment and over 70 pg/mg guanine bases by 18 h (Liu et al., 1994) , are converted to G to A mutations and results in a marked increase in tumorigenesis. We have recently shown that the O 6 -meG DNA adduct is the predominant carcinogenic lesion in MMR competent mice, and based on our data here, suggest that this is also the case for MMR de®cient mice (Allay et al., 1999) . Of interest, MMR-defective cells have been shown to have reduced numbers of chromosomal aberrations following methylating agent exposure, indicating that MMR processing of O 6 -meG may be critical to these aberrations (Galloway et al., 1995) . From this, we predict that most of the carcinogenic lesions in PMS2 7/7 mice are point mutations rather than chromosomal in nature.
High expression of hMGMT transgenes in our transgenic mice protected normal mice from lymphoma induction by MNU due to ecient removal of the methyl group from O 6 -mG (Dumenco et al., 1993; Liu et al., 1994) . We hypothesized that high expression of hMGMT should also protect MMR-de®cient mice. The protection was signi®cant (P50.05), but incomplete in PMS2 -meG to A may occur prior to the repair by AGT because cell cycle arrest is not present in the absence of MMR (Carethers et al., 1996; Davis et al., 1998; Hawn et al., 1995) . It is possible that other adducts may also contribute to lymphomagenesis, but these (N It is generally believed that ras-family gene mutations can be induced by MNU-mediated alkylation. A G to A transition mutation at the second position in codon 12 of K-ras, which results in a GGT Figure 4 Two-step PCR-RFLP procedure for detection of mouse K-ras mutation. Three to ®ve mm 3 tissue samples from thymic lymphomas were incubated overnight in 50 mM Tris, pH 8.0, 10 mM EDTA, 100 mM NaCl, 1% Triton X-100 (Sigma, St. Louis, MO, USA) and 1 mg/ml proteinase K (Gibco, Gaithersburg, MD, USA) at 558C. The digestive solution was ten times diluted and boiled for 6 min. Ten ml of the sample digest was used as substrate for the ®rst PCR ampli®cation of the ®rst exon of the K-ras oncogene (codons 4 ± 40). For PCR#2 reaction, the BstN-1 digested PCR#1 products were diluted (1 : 10) and used for ampli®cation. (A) PCR#1: The primer#1 (5'-AACTTGTGGTGG-TTGGACCTG-3') used in PCR#1 carries a point mutation (G to C) as shown by bold with the last G of the primer corresponding to the ®rst position of the codon 12 of the mouse K-ras, creating a BstN-I restriction site (CCTGG) if there is no mutation at the second position of codon 12 (GGT) of K-ras oncogene. Following BstN-I (New England Biolabs, Beverly, MA, USA) digestion, the 106 bp product of the wild type K-ras was cut to an 86 bp fragment, and a 20 bp fragment (not shown); whereas if there is any mutation at the second position (G to H) of codon 12 of Kras is not cut by BstN-I (H=A, C or T). (B) PCR#2: In the second PCR, primer #3 (5'-AACTTGTGGTGGTTGGAGCGG-3') carries a point mutation (T to G) as shown by bold with the last G of the primer corresponding to the ®rst position of the codon 12 of the mouse K-ras, resulting in a Fok-I restriction site (GGATG) if there is a G to A mutation at the second position of codon 12 of K-ras. This allele was cut by Fok-I (Boehringer Mannheim Corp., Indianapolis, IN, USA) to 45 and 35 bp fragments whereas the wild type sequence or any other non-GGT to GAT mutation remained intact. In summary, (1) Cut in the ®rst step/Uncut in the second step; there are two possibilities, (a) wild type with no mutations in K-ras and (b) mutations at the third position (T) or the ®rst position of codon 13; (2) Uncut in the ®rst step/Cut in the second step: G to A mutation at the second position of codon 12 of K-ras; (3) Uncut both in the ®rst step and in the second step: non-G to A mutation at the second position of codon 12 of K-ras; (4) Cut both in the ®rst step and in the second step: impossible combination (Y=CorT; V=A, CorG; H=A, CorT). (C) Positive and negative samples for K-ras mutation. Lane a is a known negative control. Lanes b to m are thymic lymphoma samples. Lane n is the known positive control. Lane o is a 25 bp size marker; The samples shown in lanes b and d show a homozygous pattern of K-ras mutation, while the samples in lanes i, j and m have a heterozygous K-ras mutation. All the mutant samples in the present study were not cut in the ®rst step but cut in the second step indicating the presence of a G to A mutation at the second position of codon 12 of K-ras. The electrophoretic separation was performed in 4% agarose gel (Gly) to GAT(Asp) mutation is the most commonly observed oncogene mutation occurring in MNU induced thymic lymphoma (Belinsky et al., 1989; Sakumar et al., 1983; Wang et al., 1990) . However, the frequency of K-ras mutation in MNU-induced lymphomas is dose-dependent, and accounts for only 10 ± 30% of lymphomas in genetically normal mice (Corominas et al., 1991; Romach et al., 1994) . We identi®ed three tumors containing K-ras mutation (12%) in MNU treated PMS2 +/+ mice. In addition, Newcomb et al. (1990) reported that there was no clear relation between elevated levels of ras protein and the presence of activated ras genes or with stages of the disease. In our study, although K-ras mutations were found, no correlation was present between these mutations and tumor latency in either PMS2 +/+ or PMS2 7/7 mice. This is in contrast to our recent report showing an association between K-ras mutation and shorter latency in LMO1 overexpressing mice (Allay et al., 1997) . Thus, while K-ras mutations are observed in some MNU-induced lymphomas, other oncogenes and/or inactivation of unidenti®ed tumor suppressor gene(s) may also be involved, and may complement the presence of K-ras mutations. The role that the Kras mutation plays in carcinogenesis might be dierent in dierent tumors, especially in animals with genomic instability, although there was no clear phenotypic or temporal relationship observed in K-ras mutant tumors compared to those without K-ras mutations. However, our current results demonstrated that more K-ras mutations were detected in MNU-treated PMS2 7/7 mice than PMS2 +/+ mice, suggesting there is a great likelihood that a cell carrying a transforming K-ras mutation will survive since O 6 -mG:T mismatches are not cytotoxic in these mice whereas they are in PMS2 +/+ mice. These data indicate that a greater proportion of O 6 -meG lesions formed by MNU may result in G to A mutations in surviving cells in PMS2 7/7 mice compared to normal mice. There may also be an increase in point mutations or strand slippage in other genes besides K-ras leading to thymic lymphomas. In PMS2 7/7 /hMGM + mice, the small number of persistent O 6 -mG lesions may more likely result in transforming K-ras mutations because of improved cell survival (Corominas et al., 1991; Newcomb et al., 1990; Romach et al., 1994) . The recent observation that aberrant expression of Rhombotin-2 (LMO-2) and Tal-1 (SCL) is associated with spontaneous development of murine lymphomas in MSH2-de®cient mice (Lowsky et al., 1997) , indicates that other genes may also be candidate genes involved in MNU induced lymphomas in PMS2 7/7 mice. Finally, some of the tumors from PMS2 7/7 mice showed a homozygous pattern of K-ras mutations although in previous studies, K-ras mutations are usually heterozygous because a single activating mutation may be transforming. The presence of homozygous K-ras mutations may indicate loss of the normal allele either spontaneously or more likely as a direct result of PMS2 de®ciency-associated genomic instability.
In summary, PMS2 7/7 mice are hypersensitive to MNU induced lymphomagenesis and are partially protected by hMGMT overexpression. These data indicate that methylation damage to DNA, either endogenous or environmental, is signi®cantly more carcinogenic in the absence of mismatch repair.
Abbreviations AGT, O6-alkylguanine DNA-alkyltransferase protein; hMGMT, human methylguanine DNA-methyltransferase gene; MMR, mismatch repair; MNU, N-methyl-N-nitrosourea 
